Please read carefully before proceeding
1. Non-legal Professional Advice. The Bridge BioHealth Unbiased Decision Tool ("Tool") is provided for informational and educational purposes only. Outputs generated by this Tool do not constitute scientific, medical, legal, financial, regulatory, or investment advice. No consultant-client or advisor-client relationship is created by use of this Tool.
2. No Guarantee of Accuracy. Scoring and recommendations are generated algorithmically based on user-submitted data. Bridge BioHealth Consulting LLC makes no representations or warranties, express or implied, regarding the accuracy, completeness, reliability, or fitness for a particular purpose of any output. Results should be independently verified by qualified professionals.
3. Confidentiality & Data Handling. This Tool is designed to operate without requiring disclosure of proprietary compound structures, trade secrets, or identifying information. Users are strongly encouraged to anonymize or de-identify all submissions. Bridge BioHealth does not store, share, or sell submitted data. However, users assume full responsibility for any information they choose to disclose.
4. No Liability. Bridge BioHealth Consulting LLC, its officers, employees, and affiliates shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising from reliance on Tool outputs, including but not limited to project decisions, resource allocation, or regulatory submissions.
5. Intellectual Property. Submitting data to this Tool does not transfer any intellectual property rights to Bridge BioHealth. Users retain all rights to their submitted information.
6. Regulatory Compliance. This Tool is not intended to substitute for FDA, EMA, or other regulatory agency guidance. Users are solely responsible for compliance with applicable laws and regulations.
7. Jurisdiction. This Tool is operated from the United States. Use of this Tool is governed by the laws of the State of Delaware, without regard to conflict of law principles.
Submit your biotech, pharma, or science project data for a structured, evidence-based, unbiased assessment. No identifiers required. No bias. Just science.
Built for biotech labs, pharma discovery teams, academic researchers, computational chemists, and AI-driven drug discovery programs. Whether your lead came from a neural network, a fragment screen, or a theoretical model — we evaluate the evidence, not the source.
Step 1 of 6
Anonymization Recommended
Do not enter compound names, CAS numbers, proprietary structures, or any identifying information. Use a project alias or code name only. This protects your IP.
Use an internal code (e.g., "Project Falcon", "BBH-2026-A"). Do not use compound names.
No Identifiers Needed
Submit without compound names, structures, or proprietary data
No Data Stored
Your submission is processed locally and never saved to our servers
Industry-Calibrated
Scoring weights reflect published drug attrition data and industry benchmarks
Whether your lead came from a neural network, a fragment screen, or a theoretical model — we evaluate the evidence, not the source.
Evaluate AI-generated molecules, virtual screening hits, and generative model outputs against the same rigorous evidence framework as wet-lab compounds.
Submit a hypothesis-stage program for structured assessment before committing synthesis resources. Identify gaps early, when they're cheapest to fix.
HTS hits, fragment-based leads, natural product derivatives — any compound class, any target, any modality.
Antibodies, ADCs, siRNA, gene editing programs — the scoring framework adapts to modality-specific evidence requirements.
Pre-IND, Phase I, or Phase II programs seeking an unbiased external assessment before a major investment decision or partnership discussion.
Assess whether a shelved program has been de-risked enough to revisit, license, or share through the Bridge BioHealth Negative Data Hub.
Our methodology is grounded in published drug attrition research, FDA guidance documents, and industry best practices from leading pharmaceutical organizations.
Five domains are scored independently and combined using evidence-based weights that reflect the relative contribution of each factor to drug development success and failure rates.
Certain findings — genotoxicity signals, hERG liability, irreproducible data — trigger automatic NO-GO flags regardless of overall score, reflecting real regulatory and scientific showstoppers.
The tool is designed to function without any proprietary identifiers. You describe your program in general scientific terms — no compound names, CAS numbers, or structures are needed or requested.
Scores are contextualized against published industry attrition data. A score of 72+ places your program in the top quartile of early-stage programs — where ~15–25% reach Phase II.
Per-compound evaluations, multi-compound bundles, and unlimited annual subscriptions for full project portfolios.
One full Go/No-Go report for a single compound or program. Ideal for spot-checks and investor-ready assessments.
Best for lead optimization campaigns. Evaluate 5 compounds or program variants — compare side-by-side in Decision History.
Unlimited evaluations for your entire project portfolio. Designed for biotech teams, pharma discovery groups, and CROs.
Academic labs and open science contributors: contact us for subsidized access. • View full pricing details